MedTrace Logo

Eradication of H. Pylori Infection With Moxifloxacin

NCT05863858 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2023-05-18

No results posted yet for this study

Summary

The main objective of the study is to compare the effectiveness of moxifloxacin triple therapy with levofloxacin-based sequential therapy in terms of eradication rate, safety, and patient compliance.

Conditions

  • Helicobacter Pylori Infection
  • Helicobacter Pylori Infection, Susceptibility to

Interventions

DRUG

Sequential Regimen: Levofloxacin 500 mg BID, Amoxicillin 1 gm BID, omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mgBID, Tinidazole 500 mg BID, Omeprazole 20 mg BID

The eradication rate of H. Pylori with levofloxacin-based sequential therapy

DRUG

Triple Regimen: Moxifloxacin 400mg OD, Amoxicillin 1 gm BID, Omeprazole 20mgBID

The eradication rate of H. Pylori with moxifloxacin-based triple therapy

Sponsors & Collaborators

  • Iyad Naeem Muhammad, PhD

    lead OTHER

Principal Investigators

  • Iyad N Muhammad, Ph.D. · Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-12-01
Completion
2022-06-08

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05863858 on ClinicalTrials.gov